Cargando…
Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience
Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) is a severe and fatal manifestation of systemic autoimmune disorders. Therapies rely on immunomodulators but their efficacy in ILD progression remains uncertain. Nintedanib, an antifibrotic agent that slows pulmonary function decline, has...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093288/ https://www.ncbi.nlm.nih.gov/pubmed/37046439 http://dx.doi.org/10.3390/diagnostics13071221 |
_version_ | 1785023549772136448 |
---|---|
author | Boutel, Maria Boutou, Afroditi Pitsiou, Georgia Garyfallos, Alexandros Dimitroulas, Theodoros |
author_facet | Boutel, Maria Boutou, Afroditi Pitsiou, Georgia Garyfallos, Alexandros Dimitroulas, Theodoros |
author_sort | Boutel, Maria |
collection | PubMed |
description | Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) is a severe and fatal manifestation of systemic autoimmune disorders. Therapies rely on immunomodulators but their efficacy in ILD progression remains uncertain. Nintedanib, an antifibrotic agent that slows pulmonary function decline, has been approved for CTD-ILD treatment. The aim of this study was to assess the effectiveness and safety of nintedanib in CTD-ILD patients in a real-world data setting. A single-center, retrospective, and descriptive analysis of CTD-ILD patients treated with nintedanib from June 2019 to November 2022 was performed. The assessment of nintedanib treatment’s efficacy was judged solely on the evolution of pulmonary function tests (PFTs), which were evaluated before and after treatment. Twenty-one patients (67% females, median age 64 years (IQR = 9) with CTD-ILD (systemic sclerosis n = 9, rheumatoid arthritis n = 5, dermatomyositis n = 4, juvenile rheumatoid arthritis n = 1, undifferentiated CTD n = 1, interstitial pneumonia with autoimmune features n = 1), 18 of whom were on concomitant immunosuppressives, had a median follow-up period of 10 months (IQR = 5). PFTs before and after treatment did not significantly differ. The mean FVC% difference was +0.9 (sd = 7.6) and the mean DLco% difference was +3.4 (sd = 12.6), suggesting numerical improvement of PFTs. The average percentage change was −0.3% and +7.6% for FVC% and DLco%, respectively, indicating stabilization of lung function. Our real-world data across a broad spectrum of CTD-ILD suggest that nintedanib could be beneficial in combination with immunosuppressives in slowing the rate of lung function decline. |
format | Online Article Text |
id | pubmed-10093288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100932882023-04-13 Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience Boutel, Maria Boutou, Afroditi Pitsiou, Georgia Garyfallos, Alexandros Dimitroulas, Theodoros Diagnostics (Basel) Article Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) is a severe and fatal manifestation of systemic autoimmune disorders. Therapies rely on immunomodulators but their efficacy in ILD progression remains uncertain. Nintedanib, an antifibrotic agent that slows pulmonary function decline, has been approved for CTD-ILD treatment. The aim of this study was to assess the effectiveness and safety of nintedanib in CTD-ILD patients in a real-world data setting. A single-center, retrospective, and descriptive analysis of CTD-ILD patients treated with nintedanib from June 2019 to November 2022 was performed. The assessment of nintedanib treatment’s efficacy was judged solely on the evolution of pulmonary function tests (PFTs), which were evaluated before and after treatment. Twenty-one patients (67% females, median age 64 years (IQR = 9) with CTD-ILD (systemic sclerosis n = 9, rheumatoid arthritis n = 5, dermatomyositis n = 4, juvenile rheumatoid arthritis n = 1, undifferentiated CTD n = 1, interstitial pneumonia with autoimmune features n = 1), 18 of whom were on concomitant immunosuppressives, had a median follow-up period of 10 months (IQR = 5). PFTs before and after treatment did not significantly differ. The mean FVC% difference was +0.9 (sd = 7.6) and the mean DLco% difference was +3.4 (sd = 12.6), suggesting numerical improvement of PFTs. The average percentage change was −0.3% and +7.6% for FVC% and DLco%, respectively, indicating stabilization of lung function. Our real-world data across a broad spectrum of CTD-ILD suggest that nintedanib could be beneficial in combination with immunosuppressives in slowing the rate of lung function decline. MDPI 2023-03-23 /pmc/articles/PMC10093288/ /pubmed/37046439 http://dx.doi.org/10.3390/diagnostics13071221 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Boutel, Maria Boutou, Afroditi Pitsiou, Georgia Garyfallos, Alexandros Dimitroulas, Theodoros Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience |
title | Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience |
title_full | Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience |
title_fullStr | Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience |
title_full_unstemmed | Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience |
title_short | Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience |
title_sort | efficacy and safety of nintedanib in patients with connective tissue disease-interstitial lung disease (ctd-ild): a real-world single center experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093288/ https://www.ncbi.nlm.nih.gov/pubmed/37046439 http://dx.doi.org/10.3390/diagnostics13071221 |
work_keys_str_mv | AT boutelmaria efficacyandsafetyofnintedanibinpatientswithconnectivetissuediseaseinterstitiallungdiseasectdildarealworldsinglecenterexperience AT boutouafroditi efficacyandsafetyofnintedanibinpatientswithconnectivetissuediseaseinterstitiallungdiseasectdildarealworldsinglecenterexperience AT pitsiougeorgia efficacyandsafetyofnintedanibinpatientswithconnectivetissuediseaseinterstitiallungdiseasectdildarealworldsinglecenterexperience AT garyfallosalexandros efficacyandsafetyofnintedanibinpatientswithconnectivetissuediseaseinterstitiallungdiseasectdildarealworldsinglecenterexperience AT dimitroulastheodoros efficacyandsafetyofnintedanibinpatientswithconnectivetissuediseaseinterstitiallungdiseasectdildarealworldsinglecenterexperience |